Reports Q4 revenue $135.41M, consensus $129.3M. “The medical field is increasingly recognizing that Cushing’s syndrome is much more prevalent than was previously assumed. Our strong 2023 commercial results reflect that physicians are more regularly screening for hypercortisolism. The results demonstrate our ability to support these physicians as they manage this complex disease. We are confident these trends will continue and are reiterating our 2024 revenue guidance of $600 – $630 million,” said Joseph Belanoff, Corcept’s CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics Reports Latest Quarterly Results and Update
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
- Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
- CORT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call